|
1
|
You JS and Jones PA: Cancer genetics and
epigenetics: Two sides of the same coin? Cancer Cell. 22:9–20.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arrowsmith CH, Bountra C, Fish PV, Lee K
and Schapira M: Epigenetic protein families: A new frontier for
drug discovery. Nat Rev Drug Discov. 11:384–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
You JS and Han JH: Targeting components of
epigenome by small molecules. Arch Pharm Res. 37:1367–1374. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Filippakopoulos P and Knapp S: Targeting
bromodomains: Epigenetic readers of lysine acetylation. Nat Rev
Drug Discov. 13:337–356. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meyer N and Penn LZ: Reflecting on 25
years with MYC. Nat Rev Cancer. 8:976–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jackstadt R, Röh S, Neumann J, Jung P,
Hoffmann R, Horst D, Berens C, Bornkamm GW, Kirchner T, Menssen A,
et al: AP4 is a mediator of epithelial-mesenchymal transition and
metastasis in colorectal cancer. J Exp Med. 210:1331–1350. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jung P, Menssen A, Mayr D and Hermeking H:
AP4 encodes a c-MYC-inducible repressor of p21. Proc Natl Acad Sci
USA. 105:15046–15051. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jung P and Hermeking H: The c-MYC-AP4-p21
cascade. Cell Cycle. 8:982–989. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Asangani IA, Dommeti VL, Wang X, Malik R,
Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S,
Engelke C, et al: Therapeutic targeting of BET bromodomain proteins
in castration-resistant prostate cancer. Nature. 510:278–282. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Delmore JE, Issa GC, Lemieux ME, Rahl PB,
Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et
al: BET bromo-domain inhibition as a therapeutic strategy to target
c-Myc. Cell. 146:904–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zuber J, Shi J, Wang E, Rappaport AR,
Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al:
RNAi screen identifies Brd4 as a therapeutic target in acute
myeloid leukaemia. Nature. 478:524–528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lockwood WW, Zejnullahu K, Bradner JE and
Varmus H: Sensitivity of human lung adenocarcinoma cell lines to
targeted inhibition of BET epigenetic signaling proteins. Proc Natl
Acad Sci USA. 109:19408–19413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rakha EA, Reis-Filho JS and Ellis IO:
Basal-like breast cancer: A critical review. J Clin Oncol.
26:2568–2581. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ignatiadis M and Sotiriou C: Luminal
breast cancer: From biology to treatment. Nat Rev Clin Oncol.
10:494–506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bihani T, Ezell SA, Ladd B, Grosskurth SE,
Mazzola AM, Pietras M, Reimer C, Zinda M, Fawell S and D'Cruz CM:
Resistance to everolimus driven by epigenetic regulation of MYC in
ER+ breast cancers. Oncotarget. 6:2407–2420. 2015.
View Article : Google Scholar
|
|
17
|
Stratikopoulos EE, Dendy M, Szabolcs M,
Khaykin AJ, Lefebvre C, Zhou MM and Parsons R: Kinase and BET
inhibitors together clamp inhibition of PI3K signaling and overcome
resistance to therapy. Cancer Cell. 27:837–851. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang MJ, Cheng YC, Liu CR, Lin S and Liu
HE: A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle
arrest, apoptosis, and myeloid differentiation of human acute
myeloid leukemia. Exp Hematol. 34:1480–1489. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mo H and Henriksson M: Identification of
small molecules that induce apoptosis in a Myc-dependent manner and
inhibit Myc-driven transformation. Proc Natl Acad Sci USA.
103:6344–6349. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Belkina AC and Denis GV: BET domain
co-regulators in obesity, inflammation and cancer. Nat Rev Cancer.
12:465–477. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Filippakopoulos P, Qi J, Picaud S, Shen Y,
Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et
al: Selective inhibition of BET bromodomains. Nature.
468:1067–1073. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lovén J, Hoke HA, Lin CY, Lau A, Orlando
DA, Vakoc CR, Bradner JE, Lee TI and Young RA: Selective inhibition
of tumor oncogenes by disruption of super-enhancers. Cell.
153:320–334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hnisz D, Abraham BJ, Lee TI, Lau A,
Saint-André V, Sigova AA, Hoke HA and Young RA: Super-enhancers in
the control of cell identity and disease. Cell. 155:934–947. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hnisz D, Schuijers J, Lin CY, Weintraub
AS, Abraham BJ, Lee TI, Bradner JE and Young RA: Convergence of
developmental and oncogenic signaling pathways at transcriptional
super-enhancers. Mol Cell. 58:362–370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gong H, Han S, Yao H, Zhao H and Wang Y:
AP-4 predicts poor prognosis in non small cell lung cancer. Mol Med
Rep. 10:336–340. 2014.PubMed/NCBI
|
|
26
|
Chou C, Pinto AK, Curtis JD, Persaud SP,
Cella M, Lin CC, Edelson BT, Allen PM, Colonna M, Pearce EL, et al:
c-Myc-induced transcription factor AP4 is required for host
protection mediated by CD8+ T cells. Nat Immunol.
15:884–893. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jackstadt R and Hermeking H: AP4 is
required for mitogen- and c-MYC-induced cell cycle progression.
Oncotarget. 5:7316–7327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jackstadt R, Jung P and Hermeking H: AP4
directly downregulates p16 and p21 to suppress senescence and
mediate transformation. Cell Death Dis. 4. pp. e7752013, View Article : Google Scholar
|
